Comparison of intravenous haloperidol and midazolam effects on patients' symptoms with conversion disorders referred to emergency department

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015100712050N2

Enrollment

140

Registered

2016-01-25

Start date

2015-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

conversion disorders. Dissociative [conversion] disorders

Interventions

Intervention 1: intervention group 1: intravenous haloperidol 2.5 mg stat. Intervention 2: intervention group 2: intravenous midazolam 2.5 mg stat.

Treatment - Drugs

intervention group 1: intravenous haloperidol 2.5 mg stat

intervention group 2: intravenous midazolam 2.5 mg stat

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: all patients aged 18 -60 years old with conversion disorders referred to emergency department in 1394-1396. Exclusion criteria: patients with abnormal vital signs; younger than 18 and older than 60 years old; pregnancy; history of drug abuse; hepatic and renal disorders; history of epilepsy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sensory disorder. Timepoint: before and after intervention. Method of measurement: observational.;Movement disorder. Timepoint: before and after intervention. Method of measurement: observational.;Consciousness disorder. Timepoint: before and after intervention. Method of measurement: observational.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Ali Jafari Nodoshan

Shahid Sadoughi University of Medical Sciences

malijafari@ssu.ac.ir+98 35 3822 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026